• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基层医疗中的远程 COVID-19 评估(RECAP)风险预测工具:推导和真实世界验证研究。

Remote COVID-19 Assessment in Primary Care (RECAP) risk prediction tool: derivation and real-world validation studies.

机构信息

Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, London, UK.

Institute of Global Health Innovation, Department of Surgery and Cancer, Imperial College London, London, UK; Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's Clinical Trials Unit, King's College London, London, UK.

出版信息

Lancet Digit Health. 2022 Sep;4(9):e646-e656. doi: 10.1016/S2589-7500(22)00123-6. Epub 2022 Jul 28.

DOI:10.1016/S2589-7500(22)00123-6
PMID:35909058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9333950/
Abstract

BACKGROUND

Accurate assessment of COVID-19 severity in the community is essential for patient care and requires COVID-19-specific risk prediction scores adequately validated in a community setting. Following a qualitative phase to identify signs, symptoms, and risk factors, we aimed to develop and validate two COVID-19-specific risk prediction scores. Remote COVID-19 Assessment in Primary Care-General Practice score (RECAP-GP; without peripheral oxygen saturation [SpO]) and RECAP-oxygen saturation score (RECAP-O2; with SpO).

METHODS

RECAP was a prospective cohort study that used multivariable logistic regression. Data on signs and symptoms (predictors) of disease were collected from community-based patients with suspected COVID-19 via primary care electronic health records and linked with secondary data on hospital admission (outcome) within 28 days of symptom onset. Data sources for RECAP-GP were Oxford-Royal College of General Practitioners Research and Surveillance Centre (RCGP-RSC) primary care practices (development set), northwest London primary care practices (validation set), and the NHS COVID-19 Clinical Assessment Service (CCAS; validation set). The data source for RECAP-O2 was the Doctaly Assist platform (development set and validation set in subsequent sample). The two probabilistic risk prediction models were built by backwards elimination using the development sets and validated by application to the validation datasets. Estimated sample size per model, including the development and validation sets was 2880 people.

FINDINGS

Data were available from 8311 individuals. Observations, such as SpO, were mostly missing in the northwest London, RCGP-RSC, and CCAS data; however, SpO was available for 1364 (70·0%) of 1948 patients who used Doctaly. In the final predictive models, RECAP-GP (n=1863) included sex (male and female), age (years), degree of breathlessness (three point scale), temperature symptoms (two point scale), and presence of hypertension (yes or no); the area under the curve was 0·80 (95% CI 0·76-0·85) and on validation the negative predictive value of a low risk designation was 99% (95% CI 98·1-99·2; 1435 of 1453). RECAP-O2 included age (years), degree of breathlessness (two point scale), fatigue (two point scale), and SpO at rest (as a percentage); the area under the curve was 0·84 (0·78-0·90) and on validation the negative predictive value of low risk designation was 99% (95% CI 98·9-99·7; 1176 of 1183).

INTERPRETATION

Both RECAP models are valid tools to assess COVID-19 patients in the community. RECAP-GP can be used initially, without need for observations, to identify patients who require monitoring. If the patient is monitored and SpO is available, RECAP-O2 is useful to assess the need for treatment escalation.

FUNDING

Community Jameel and the Imperial College President's Excellence Fund, the Economic and Social Research Council, UK Research and Innovation, and Health Data Research UK.

摘要

背景

准确评估社区内 COVID-19 的严重程度对于患者的治疗至关重要,这需要 COVID-19 特异性风险预测评分在社区环境中得到充分验证。在进行了定性阶段以确定体征、症状和危险因素之后,我们旨在开发和验证两个 COVID-19 特异性风险预测评分。远程 COVID-19 初级保健-全科医学评估评分(RECAP-GP;不包括外周血氧饱和度[SpO])和 RECAP-血氧饱和度评分(RECAP-O2;包括 SpO)。

方法

RECAP 是一项前瞻性队列研究,使用多变量逻辑回归。通过初级保健电子健康记录从疑似 COVID-19 的社区患者中收集疾病的体征和症状(预测因素)数据,并将其与发病后 28 天内的住院(结局)的二级数据相关联。RECAP-GP 的数据源是牛津-皇家全科医师学院研究和监测中心(RCGP-RSC)初级保健实践(开发集)、伦敦西北部初级保健实践(验证集)和 NHS COVID-19 临床评估服务(CCAS;验证集)。RECAP-O2 的数据源是 Doctaly Assist 平台(开发集和随后的样本中的验证集)。这两个概率风险预测模型通过向后消除法使用开发集构建,并通过在验证数据集上的应用进行验证。每个模型的估计样本量(包括开发集和验证集)为 2880 人。

结果

从 8311 个人中获得了数据。观察值,如 SpO,在伦敦西北部、RCGP-RSC 和 CCAS 数据中大多缺失;然而,Doctaly 使用的 1948 名患者中有 1364 名(70.0%)提供了 SpO。在最终的预测模型中,RECAP-GP(n=1863)包括性别(男性和女性)、年龄(岁)、呼吸困难程度(三分制)、体温症状(二分制)和高血压存在情况(是或否);曲线下面积为 0.80(95%CI 0.76-0.85),在验证中,低风险指定的阴性预测值为 99%(95%CI 98.1-99.2;1435 例中的 1453 例)。RECAP-O2 包括年龄(岁)、呼吸困难程度(二分制)、疲劳(二分制)和休息时的 SpO(百分比);曲线下面积为 0.84(0.78-0.90),在验证中,低风险指定的阴性预测值为 99%(95%CI 98.9-99.7;1176 例中的 1183 例)。

解释

这两个 RECAP 模型都是评估社区内 COVID-19 患者的有效工具。RECAP-GP 可以首先使用,无需观察,以识别需要监测的患者。如果患者得到监测并且可以获得 SpO,那么 RECAP-O2 可用于评估是否需要升级治疗。

资助

社区贾米尔和帝国学院校长卓越基金、英国经济与社会研究理事会、英国研究与创新署以及英国健康数据研究署。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/8336a4833f56/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/2d5abe4fd0b3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/e64b6821443c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/8336a4833f56/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/2d5abe4fd0b3/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/e64b6821443c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e287/9333950/8336a4833f56/gr3_lrg.jpg

相似文献

1
Remote COVID-19 Assessment in Primary Care (RECAP) risk prediction tool: derivation and real-world validation studies.基层医疗中的远程 COVID-19 评估(RECAP)风险预测工具:推导和真实世界验证研究。
Lancet Digit Health. 2022 Sep;4(9):e646-e656. doi: 10.1016/S2589-7500(22)00123-6. Epub 2022 Jul 28.
2
Predicting Risk of Hospital Admission in Patients With Suspected COVID-19 in a Community Setting: Protocol for Development and Validation of a Multivariate Risk Prediction Tool.预测社区环境中疑似新型冠状病毒肺炎患者的住院风险:多变量风险预测工具的开发与验证方案
JMIR Res Protoc. 2021 May 25;10(5):e29072. doi: 10.2196/29072.
3
An Early Warning Risk Prediction Tool (RECAP-V1) for Patients Diagnosed With COVID-19: Protocol for a Statistical Analysis Plan.用于新冠肺炎确诊患者的早期预警风险预测工具(RECAP-V1):统计分析计划方案
JMIR Res Protoc. 2021 Oct 5;10(10):e30083. doi: 10.2196/30083.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Development and validation of a risk prediction model for hospital admission in COVID-19 patients presenting to primary care.开发和验证针对到基层医疗就诊的 COVID-19 患者的住院风险预测模型。
Eur J Gen Pract. 2024 Dec;30(1):2339488. doi: 10.1080/13814788.2024.2339488. Epub 2024 Apr 29.
6
What items should be included in an early warning score for remote assessment of suspected COVID-19? qualitative and Delphi study.疑似 COVID-19 远程评估的早期预警评分应包含哪些项目?定性和德尔菲研究。
BMJ Open. 2020 Nov 12;10(11):e042626. doi: 10.1136/bmjopen-2020-042626.
7
Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.创建改良版剑桥多病种评分以预测 16 岁以上人群的死亡率:模型的建立和验证。
J Med Internet Res. 2024 Aug 26;26:e56042. doi: 10.2196/56042.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
The Development and Validation of Simplified Machine Learning Algorithms to Predict Prognosis of Hospitalized Patients With COVID-19: Multicenter, Retrospective Study.中文译文:简化机器学习算法预测 COVID-19 住院患者预后的开发和验证:多中心回顾性研究。
J Med Internet Res. 2022 Jan 21;24(1):e31549. doi: 10.2196/31549.
10
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary.英国牛津-皇家全科医师学院研究和监测网络 2020-2021 年的代表性、疫苗接种率和 COVID-19 临床结局:队列简介摘要。
JMIR Public Health Surveill. 2022 Dec 19;8(12):e39141. doi: 10.2196/39141.

引用本文的文献

1
Comparison of the ALKA and CRS scores to predict outcomes among patients with coronavirus disease 2019 infection in United Arab Emirates.比较ALKA和CRS评分以预测阿拉伯联合酋长国2019冠状病毒病感染患者的预后。
Front Med (Lausanne). 2025 Aug 18;12:1553189. doi: 10.3389/fmed.2025.1553189. eCollection 2025.
2
Development and validation of a risk prediction model for hospital admission in COVID-19 patients presenting to primary care.开发和验证针对到基层医疗就诊的 COVID-19 患者的住院风险预测模型。
Eur J Gen Pract. 2024 Dec;30(1):2339488. doi: 10.1080/13814788.2024.2339488. Epub 2024 Apr 29.
3
RECAP-KG: Mining Knowledge Graphs from Raw Primary Care Physician Notes for Remote COVID-19 Assessment in Primary Care.

本文引用的文献

1
Effectiveness and safety of pulse oximetry in remote patient monitoring of patients with COVID-19: a systematic review.脉搏血氧仪在 COVID-19 远程患者监测中对患者的有效性和安全性:系统评价。
Lancet Digit Health. 2022 Apr;4(4):e279-e289. doi: 10.1016/S2589-7500(21)00276-4.
2
Assessing the safety of home oximetry for COVID-19: a multisite retrospective observational study.评估 COVID-19 家庭血氧仪的安全性:一项多中心回顾性观察研究。
BMJ Open. 2021 Sep 14;11(9):e049235. doi: 10.1136/bmjopen-2021-049235.
3
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
RECAP-KG:从原始初级保健医生笔记中挖掘知识图,用于初级保健中的远程 COVID-19 评估。
AMIA Annu Symp Proc. 2024 Jan 11;2023:1145-1154. eCollection 2023.
在 COVID 症状研究应用程序的英国用户中,疫苗接种后 SARS-CoV-2 感染的风险因素和疾病特征:一项前瞻性、基于社区的、嵌套的病例对照研究。
Lancet Infect Dis. 2022 Jan;22(1):43-55. doi: 10.1016/S1473-3099(21)00460-6. Epub 2021 Sep 1.
4
An Early Warning Risk Prediction Tool (RECAP-V1) for Patients Diagnosed With COVID-19: Protocol for a Statistical Analysis Plan.用于新冠肺炎确诊患者的早期预警风险预测工具(RECAP-V1):统计分析计划方案
JMIR Res Protoc. 2021 Oct 5;10(10):e30083. doi: 10.2196/30083.
5
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.在英国社区中有并发症高风险的人群中使用布地奈德吸入剂治疗 COVID-19(PRINCIPLE):一项随机、对照、开放标签、适应性平台试验。
Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10.
6
Predicting Risk of Hospital Admission in Patients With Suspected COVID-19 in a Community Setting: Protocol for Development and Validation of a Multivariate Risk Prediction Tool.预测社区环境中疑似新型冠状病毒肺炎患者的住院风险:多变量风险预测工具的开发与验证方案
JMIR Res Protoc. 2021 May 25;10(5):e29072. doi: 10.2196/29072.
7
Consequences of the emergency response to COVID-19: a whole health care system review in a single city in the United Kingdom.应对 COVID-19 疫情的后果:英国一个城市对整个医疗保健系统的审查。
BMC Emerg Med. 2021 May 1;21(1):55. doi: 10.1186/s12873-021-00450-2.
8
Systemic and organ-specific immune-related manifestations of COVID-19.COVID-19 的全身性和器官特异性免疫相关表现。
Nat Rev Rheumatol. 2021 Jun;17(6):315-332. doi: 10.1038/s41584-021-00608-z. Epub 2021 Apr 26.
9
Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: a multi-hospital study.评估和改进 COVID-19 的国家早期预警评分(NEWS2):一项多医院研究。
BMC Med. 2021 Jan 21;19(1):23. doi: 10.1186/s12916-020-01893-3.
10
What items should be included in an early warning score for remote assessment of suspected COVID-19? qualitative and Delphi study.疑似 COVID-19 远程评估的早期预警评分应包含哪些项目?定性和德尔菲研究。
BMJ Open. 2020 Nov 12;10(11):e042626. doi: 10.1136/bmjopen-2020-042626.